OGN Organon & Co.

Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.

$31.13  -0.41 (-1.30%)
As of 11/26/2021 13:00:52 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—General
Index country:  USA
Country of incorporation:  USA
IPO date:  05/14/2021
Outstanding shares:  253,550,029
Average volume:  2,391,459
Market cap:   $7,996,967,915
Current dividend yield:  1.77%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    68622V106
ISIN:        US68622V1061
Sedol:      BLDC8J4
Valuation   (See tab for details)
PE ratio:   6.87
PB ratio:   1.67
PS ratio:   1.02
Return on equity:   -93.76%
Net income %:   19.26%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy